|
Originally published In Press as doi:10.1074/jbc.M001538200 on July 20, 2000
J. Biol. Chem., Vol. 275, Issue 38, 29915-29921, September 22, 2000
Physical and Functional Interaction between Two Pluripotent
Proteins, the Y-box DNA/RNA-binding Factor, YB-1, and the Multivalent
Zinc Finger Factor, CTCF*
Igor V.
Chernukhin ,
Shaharum
Shamsuddin ,
Abigail F.
Robinson ,
Alexander F.
Carne§,
Angela
Paul§,
Ayman I.
El-Kady ,
Victor V.
Lobanenkov¶ , and
Elena M.
Klenova **
From the Genetics Laboratory, Department of
Biochemistry, University of Oxford, Oxford OX1 3QU, United Kingdom, the
§ Institute of Cancer Research, Haddow Laboratories, Sutton,
Surrey, United Kingdom, and the ¶ Section of Molecular Pathology,
Laboratory of Immunopathology, NIAID, National Institutes of Health,
Bethesda, Maryland 20892
Received for publication, February 23, 2000, and in revised form, June 7, 2000
 |
ABSTRACT |
CTCF is a unique, highly conserved, and
ubiquitously expressed 11 zinc finger (ZF) transcriptional
factor with multiple DNA site specificities. It is able to bind to
varying target sequences to perform different regulatory roles,
including promoter activation or repression, creating
hormone-responsive gene silencing elements, and functional block of
enhancer-promoter interactions. Because different sets of ZFs are
utilized to recognize different CTCF target DNA sites, each of the
diverse DNA·CTCF complexes might engage different essential protein
partners to define distinct functional readouts. To identify such
proteins, we developed an affinity chromatography method based on
matrix-immobilized purified recombinant CTCF. This approach resulted in
isolation of several CTCF protein partners. One of these was identified
as the multifunctional Y-box DNA/RNA-binding factor, YB-1, known to be
involved in transcription, replication, and RNA processing. We examined
CTCF/YB-1 interaction by reciprocal immunoprecipitation experiments
with anti-CTCF and anti-YB-1 antibodies, and found that CTCF and YB-1
form complexes in vivo. We show that the bacterially
expressed ZF domain of CTCF is fully sufficient to retain YB-1 in
vitro. To assess possible functional significance of CTCF/YB-1
binding, we employed the very first identified by us, negatively
regulated, target for CTCF (c-myc oncogene promoter) as a
model in co-transfection assays with both CTCF and YB-1 expression
vectors. Although expression of YB-1 alone had no effect, co-expression
with CTCF resulted in a marked enhancement of CTCF-driven
c-myc transcriptional repression. Thus our findings
demonstrate, for the first time, the biological relevance of the
CTCF/YB-1 interaction.
 |
INTRODUCTION |
Our search for conserved transcription factors that could
similarly regulate the highly divergent promoters of avian and
mammalian c-myc oncogenes resulted in identification and
cloning of the gene encoding
CTCF,1 which contains a
DNA-binding domain comprising 11 ZFs (1-6) CTCF binds to remarkably
different, ~50 bp long, DNA target sites in the promoters of chicken
and human c-myc genes (5, 6). Inspection of additional
CTCF-binding sites characterized by us and others showed that the mere
presence of the CCCTC motif is neither necessary nor sufficient for
CTCF binding (4, 6-12).
CTCF appears to act differently upon binding to functionally distinct
regulatory elements, which include: 1) enhancer-blocking (insulator)
elements in the two boundaries flanking the -globin locus, in the
T-cell receptor / locus site, and in a matrix attachment
5'-boundary of the chicken lysozyme gene (see Refs. 11, 13, and 14 for
details); 2) promoter-proximal sites in chicken, mouse, and human
c-myc proto-oncogenes (5, 6); 3) the S-2.4
lysozyme gene transcriptional silencer (8) and the 144 genomic element
(15), both of which require CTCF for efficient negative regulation by
thyroid nuclear receptors; and 4) the crucial regulatory site of the
amyloid protein precursor gene promoter (9, 16, 17). Moreover, CTCF is
recently found to be a parent of the origin-specific and
methylation-sensitive functional component of the chromatin
insulator(s) upstream of the H19 gene (12, 18, 19), thus
suggesting a new role for CTCF in the control of genomic imprinting.
CTCF-dependent insulators do not act as general
transcription repressors or activators, but, rather, block functional
interaction between an enhancer and a promoter (11-14). On the other
hand, binding of CTCF to the chicken or human c-myc major
promoter results in repression (4, 6), while binding to the APP
promoter activates transcription (9, 17). This diverse variety of functions indicates that, following the interaction with different sequences, the unique CTCF·DNA complexes might acquire
distinct conformations that behave as sequence-specific platforms for
selective binding of other proteins, which, in turn, define specific
functional role of CTCF in this setting. In support of this hypothesis,
we previously demonstrated that interaction of CTCF with two different DNA sequences of identical length results in distinct patterns of
protein protection against proteolytic attack (6).
Thus, identification of CTCF-interacting protein partners appears to be
necessary to elucidate biological consequences of CTCF binding to
different targets. To search for proteins interacting with CTCF, we
developed a reliable and simple affinity chromatography method for
fractionation of nuclear extracts on a matrix coupled with purified
CTCF protein expressed in a baculovirus system.
One of the proteins retained by, and then eluted from, this matrix was
found to be another multifunctional factor, YB-1. YB-1 is a member of
the family of Y-box binding factors with each member containing some
degree of homology to the cold shock domain (20). YB-1 is believed to
participate in regulation of such diverse functions as transcription,
replication, and RNA turnover (for reviews see Refs. 20-24). In
addition, YB-1 family members appear to be involved in mediating
effects of UV irradiation (25), drug and interleukin-2 treatments (26,
27), and DNA damage (28). Moreover, YB-1 and YB-1-like proteins
participate in DNA repair. They can also promote DNA unwinding and DNA
and RNA condensation (20, 21, 29, 30). Given these properties, we
predict that interactions between CTCF and YB-1 are likely to play
multiple roles in regulation of major cellular processes.
In our initial attempt to assess whether there is a functional
consequence of CTCF/YB-1 heterodimerization, we employed a transcriptional activity reporter system utilizing the very first CTCF-targeted promoter identified by us in the chicken c-myc
oncogene locus (2-4, 31).
We show here that, although expression of YB-1 alone had no effect on
c-myc reporter activity, co-expression of YB-1 with CTCF
resulted in a marked enhancement of CTCF-dependent
transcriptional repression. These findings provide the first example of
what may be multiple functional roles for CTCF/YB-1 interactions.
 |
EXPERIMENTAL PROCEDURES |
CTCF Expression in the Baculovirus System--
The baculovirus
expression system was utilized to obtain pure CTCF protein. To generate
baculovirus that would expresses recombinant His-tagged CTCF we
engineered the pVLH-CTCF vector based on the pVLH6 plasmid
kindly provided by R. M. Marais (CRC Center for Cell and Molecular
Biology, London). The pVLH-CTCF was co-transfected with the
Baculogold baculovirus DNA into SF9 cells, and recombinants were
selected, characterized, and amplified following the manufacturer's instructions (BacVector System Manual, Novagen). The CTCF protein (termed "baculoCTCF") was purified to 80-90% purity from infected SF9 cells using Ni-affinity chromatography with a linear gradient of
imidazole for elution and subsequent gel filtration on an S-200 column (see Fig. 1A).
BaculoCTCF Affinity Chromatography--
BaculoCTCF protein (see
Fig. 1A) served as a "molecular hook" to pull out
CTCF-interacting proteins from cell extracts. For this purpose, the
baculoCTCF was first covalently coupled to the Sepharose 4B matrix
using N-hydroxysuccinimidyl chloroformate-activated Sepharose 4B (both reagents from Sigma) to attach the protein. The
protein solution was dialyzed against 1 M NaCl/0.1
M Na2HPO4, pH 8.2, and mixed with
the activated resin in a protein/matrix ratio of 2 mg/1 ml. The binding
reaction was performed overnight at +4 °C. The suspension was
filtered to remove non-incorporated material and then blocked with 1 M ethanolamine, pH 8.2. Next, cell extracts were obtained
from the chicken erythroid precursor cells HD3 (32) in buffer
containing 50 mM Tris/HEPES, pH 8.0, 1% Nonidet P-40, 2 mM EDTA, 0.5 M NaCl, and 1 mM
phenylmethylsulfonyl fluoride and incubated at 4 °C for 30 min. An
equal amount of the same buffer without NaCl or Nonidet P-40 was added,
and the lysates were clarified by centrifugation at 15,000 × g for 10 min. The cleared extracts in the 0.25 M NaCl-containing buffer were passed through the
baculoCTCF affinity column. Weakly bound proteins were washed off with
the low-salt buffer while strongly interacting proteins were
subsequently eluted with the same buffer containing 1 M NaCl.
Identification of the Proteins Obtained by CTCF Affinity
Chromatography--
The eluted baculoCTCF-interacting partners were
resolved by SDS-PAGE and visualized by Coomassie Blue staining. Well
resolved protein bands were excised from gels and subjected to the
"in-gel" digestion according to the method previously described by
Shevchenko and colleagues (33). The MALDI-MS system on the LaserMat
2000 (ThermoBioAnalysis, Middlesex, UK) was utilized to map the mass of
the tryptic mixture derived from each band (34). The mass values
obtained by the analysis of the tryptic digests were used to inspect
the SwissProt protein data base using the MS-Fit program available on
the WEB from the UCSF Mass Spectrometry Facility. One of the
proteins was tentatively identified as the Y box binding protein-1
(YB-1).
Immunoprecipitation--
For immunoprecipitation, HeLa cells
(~2 × 106) were collected, washed twice with the
ice-cold phosphate-buffered saline, and lysed in 500 µl of high salt
RIPA buffer containing 0.5 M NaCl, 50 mM
Tris-HEPES (pH 7.5), 1% Nonidet P-40, 2 mM EDTA,
supplemented with 1 mM of phenylmethylsulfonyl fluoride, as
described previously (35). After incubation for 30 min at 4 °C, 500 µl of RIPA buffer without NaCl was added to cell lysates, which were
then cleared by centrifugation at 15,000 × g for 10 min. CTCF and YB-1 were immunoprecipitated, respectively, by polyclonal
affinity-purified rabbit antibodies to CTCF (Upstate Biotechnology,
Lake Placid, NY) and YB-1 (kindly provided by H.-D. Royer and A. Lee
(36)). The anti-CTCF antibodies were raised against the bacterially
expressed human CTCF carboxyl-terminal domain and recognize CTCF
in all vertebrates due to the exceptionally high evolutionarily
conservation of CTCF protein sequence (5,
6). Other antibodies for
co-immunoprecipitation experiments were used against several nuclear
proteins, including p21, ubiquitous nuclear receptor UR, thyroid
receptor TR , hTAF II 130, and MYC (Santa Cruz Biotechnology, Santa
Cruz, CA).
The immunoprecipitates obtained with the rabbit polyclonal antibodies
were then incubated with 20 µl of protein A-Sepharose-4B-Fast (Sigma), while the precipitates obtained with the mouse monoclonal antibodies were incubated with 20 µl of protein G-Sepharose-CL4B (Sigma) for 1 h at 4 °C. The Sepharose beads were then washed five times with 1 ml of RIPA buffer containing 0.25 M NaCl.
Immobilized proteins were resolved by 10% SDS-PAGE, transferred onto
Immobilon P membranes (Millipore), and probed by Western blot analysis
procedure as described below.
Expression of the Amino-terminal, Zinc Finger, and
Carboxyl-terminal Domains of CTCF in Bacterial System--
We
initially prepared the pCITE4b-hCTCF-C plasmid containing the
0.8-kbp NcoI to EaeI DNA fragment from the
p7.1 human CTCF cDNA plasmid (6) cloned into the NcoI
and NotI sites of pCITE-4b (Novagen, Madison, WI) downstream
of the viral cap independent translational enhancer (CITE). This vector
encodes the carboxyl-terminal domain of CTCF extending from the Met
residue in the middle of the 11th zinc finger to the stop codon (amino
acids 589-727, see Fig. 4A). Next, we constructed a
bacterial expression vector pET16b-CTCF-C for purification of the
His-tagged CTCF-C protein. The NdeI-XhoI DNA
fragment from the pCITE4b-hCTCF-C plasmid was re-ligated to the
NdeI and XhoI ends of the pET16b (Novagen)
resulting in pET/hCTCF-C. This vector contains, under an inducible
promoter, a coding region for the in-frame fusion between the His-Tag
polypeptide,
Met-Gly-(His10-tag)-Ser-Ser-Gly-His-Ile-Glu-Arg-His, the S-tag polypeptide derived from the pCITE4b, and the hCTCF-C region.
To improve the coupling of the bacterially expressed proteins to the
matrix, we modified the parental plasmid pET16b-CTCF-C to
pET16b-CTCF-C+cys by adding a tag composed of four cysteine residues.
To this end, the pET16b-CTCF-C plasmid was cut with AgeI and XhoI enzymes, and the backbone
was then re-ligated with the double stranded annealed DNA fragment
5'-CCGG-TGT-TGC-TGT-TGC-TAG-CTA-AC-3' encoding the tag created by the four-cysteine amino acids
(underlined) in-frame with the end of the CTCF protein,
followed by the stop codon and flanked by the AgeI and
XhoI (shown in bold italic) sites for cloning into
pET16b-CTCF-C digested with AgeI plus XhoI. The
resulting plasmid was named pET16b-CTCF-C+cys, and its vector backbone
obtained after digestion with NdeI and AgeI
enzymes was utilized to produce the pET16b-CTCF-N+cys and
p16b-CTCF-Zn+cys vectors for expression of the CTCF amino-terminal and
zinc finger domains, respectively (see Fig. 4A). The
corresponding domains were polymerase chain reaction-amplified from the
pCI7.1 vector (6) with primers containing a NdeI restriction
site in-frame with the pET16b translation start codon and
AgeI at the stop site. The primers were (NdeI and
AgeI sites are underlined): 1) for the
CTCF amino-terminal domain (amino acids 1-278) (see Fig.
4A), the forward primer (NdeI, nucleotides 279-300, numbering according to ref. 6),
5'-AGAGGCAGGGCATATGGAAGGT-3', and the reverse primer
(AgeI, nucleotides 1125-1105),
5'-ACGCCGTGGACACCGGTAACT-3'; or for the CTCF zinc finger
domain (amino acids 264-584) (see Fig. 4A), the forward
primer (NdeI) (nucleotides 1081-1104),
5'-AAGACATTCCAGCATATGCTTTGC-3' with the reverse primer
(AgeI) (nucleotides 2043-2023),
5'-CTCTACGCCATACCGGTCAGC-3'. The polymerase chain
reaction-produced DNA fragments, corresponding to the amino- and Zn-
domains of CTCF, were then cut with NdeI and AgeI
and ligated into the pET16b-CTCF-C+cys vector digested with
NdeI and AgeI so that the four Cys residues
remained in the backbone of the vector. The resulting plasmids,
pCTCF-ZF+cys and pCTCF-N+cys, were verified by sequencing and
transformed into Escherichia coli strain BL21 (DE3)
purchased from Invitrogen (Carlsbad, CA).
Expression in E. coli and Purification of the Amino-terminal,
Zinc Finger, and Carboxyl-terminal Domain of CTCF--
Transformants
carrying the plasmids expressing the three CTCF distinct regions, were
grown in LB media supplemented with ampicillin (50 µg/ml) for 3 h at 37 °C. Protein expression was induced by the addition of 0.4 mM isopropyl -D-thiogalactoside with further incubation for 3 h at 37 °C. For purification of each of the
desired protein, the bacterial cells were pelleted, washed twice with 0.1 volume of cold phosphate-buffered saline followed by lysis in 0.1 volume of the original culture in the cold fresh lysis buffer
containing 8 M urea, 0.1 M
NaH2PO4, 0.01 M Tris-HCl, pH 8.0. The lysates were subjected to immobilized metal ion affinity chromatography for further purification. Total bacterial lysates containing His-tag expressed proteins were 1) supplemented with 20 mM imidazole; 2) loaded onto the nickel-charged His-Bind
resin (R&D Systems, Europe Ltd.); 3) washed with one bed volume of the washing buffer containing 8 M urea, 0.1 M
NaH2PO4, 0.01 M Tris-HCl, pH 8.0, and 20 mM imidazole; 4) finally, the His-tagged proteins were eluted by10 ml of the buffer with 8 M urea, 0.1 M NaH2PO4, 0.01 M
Tris-HCl, pH 8.0, and 0.5 M imidazole. Purity and identity of the isolated proteins were verified by 10% SDS-PAGE followed by
Coomassie Blue staining and Western blot assays with anti-His-tag (H-3)
antibodies (Santa Cruz Biotechnology, Santa Cruz, CA).
Immobilization of the Bacterially Expressed Amino-terminal, Zinc
Finger, and Carboxyl-terminal Domains of CTCF on the
Matrix--
Cystamine-coupled Sepharose 4B was utilized to bind the
bacterially produced distinct CTCF domains shown below in Fig.
4A. Cystamine was first converted into aminoethylthiol by a
reducing reaction with 50 mM dithiothreitol in TE buffer
(50 mM Tris-EDTA, pH 8.3) for 30 min at room temperature,
then treated with 5 mM 2,2-dipyridyldisulfide for 2 h.
The activated matrix was washed with the TE buffer. Each protein was
reduced by incubation with 5 mM dithiothreitol for 1 h
at room temperature, passed through a G50 column equilibrated with TE
to desalt the proteins, and then incubated with the activated matrix
overnight at +4 °C at a protein to Sepharose v/w ratio of 5 mg/1 ml.
The amounts of the proteins retained on the matrix were monitored by
protein assay (Bio-Rad) according to the manufacturer's instructions. The protein-Sepharose conjugates were finally washed with the TE buffer
to remove non-incorporated materials and stored in the buffer
containing 20% glycerol, 50 mM
KH2PO4, pH 7.0, and 0.2% Na3N.
Interaction Assay--
On a rotating platform, we incubated
~50 µl of the Sepharose suspension carrying each of different of
CTCF protein domains (see Fig. 4A) mixed with 1 ml of HeLa
lysate in 0.25 M RIPA buffer for at least 6 h.
Each suspension was then washed six times with 0.25 M RIPA
buffer, boiled in SDS sample-loading solution for 5 min, run on 10%
SDS-PAGE, and Western blotted. The presence of the CTCF-interacting
partner, YB-1, was detected with anti-YB1 antibodies.
Preparation of Nuclear Extracts and Electrophoretic Mobility
Shift Assay--
Nuclear extracts were prepared according to
procedures described in detail previously (37). A
32P-labeled DNA probe (~1 ng), the chicken
c-myc fragment FPV harboring the binding site V for CTCF,
was prepared by labeling with T4 polynucleotide kinase and
[ -32P]ATP as described previously (5, 38). The probe
was incubated in 1× EMSA binding buffer (the 5× EMSA binding buffer
stock contained 20% Ficoll, 30 mM NaCl, 100 mM
HEPES, pH 7.85, and 1 mM MgCl2) with purified
baculoCTCF protein, nuclear extracts prepared from COS6 cells, or with
no protein as a control, in the presence of nonspecific double-stranded
competitors poly(dI-dC) (200 µg) and poly(dG-dC) (40 µg) in a total
volume of 20 µl. This EMSA reaction mixture was kept on ice for 30 min and loaded on the 10% native polyacrylamide gel. The samples were
run in 0.33× TBE at 250 V (~25 mA) for 2 h. The gel was fixed
in 10% glacial acetic acid with 20% methanol, dried, and exposed to
the XAR-5 film (Kodak).
Western Blot Analysis--
Proteins resolved on the 10%
SDS-PAGE gels were transferred to Immobilon P polyvinylidene
difluoride filters (Millipore) by electroblotting.
Membranes were incubated with the primary antibody (at 1:200 dilution
for the anti-CTCF and 1:5000 dilution for the anti-YB-1 antibodies) for
1 h at room temperature. After washing, the membranes were
incubated with anti-rabbit-peroxidase-conjugated antibodies (1:10,000
dilution) for 1 h at room temperature and then processed following
the manufacturer's instructions for the enhanced
chemiluminescence detection (ECL kit, Amersham Pharmacia Biotech).
Cell Culture, Transient Transfections, and CAT Assay--
On the
day prior to transfection, COS6 cells were plated at a density of
105 cells/well using12-well plates (Corning), and
maintained overnight in Dulbecco's modified Eagle's medium
supplemented with 10% fetal bovine serum. On the day of transfection
the cells were ~80% confluent. A standard calcium phosphate DNA
transfection method was utilized. Measurements of chloramphenicol
acetyl transferase (CAT) activity produced by the reporters in equal
numbers of the transfected cells were carried out as described
previously earlier (5, 38).
 |
RESULTS |
We wished to determine whether CTCF is involved in protein-protein
interactions and to identify different CTCF-binding factors. For this
purpose, we developed an affinity chromatography approach that utilizes
the matrix coupled with the CTCF protein produced in the baculovirus
expression system. In addition to high specificity, another advantage
of this approach is that the same CTCF matrix can be reused for
isolation of CTCF partners from different cell extracts.
Expression and Purification of the Full-length CTCF
Protein--
The baculovirus expression system was employed to
generate the CTCF protein in quantities sufficient for immobilization
of CTCF on the matrix. Approximately 5 mg of ~90% pure full-length His-tagged baculoCTCF protein (schematically depicted in Fig. 4A) was obtained (Fig. 1). In
contrast to bacterially produced full-length CTCF that forms aggregates
difficult to solubilize into properly refolded individual CTCF
molecules,2 baculoCTCF
apparently has the native conformation. In comparisons with the
endogenous CTCF, the 6xHis-baculoCTCF has the same major biochemical
activities (Fig. 1). First, baculoCTCF co-migrates as the endogenous
CTCF in SDS-PAGE. Second, anti-CTCF antibodies recognize it equally
well. Third, it has DNA-binding properties identical to that of the
endogenous CTCF as demonstrated by EMSA (Fig. 1C). Thus, the
isolated full-length His-tagged baculoCTCF protein appears to be in the
native conformation. This property is of obvious importance for use as
the molecular bait in a search for interacting partners.

View larger version (51K):
[in this window]
[in a new window]
|
Fig. 1.
CTCF, expressed in a baculovirus system
(baculoCTCF) has the same biochemical characteristics as the endogenous
CTCF. A, analysis of the baculoCTCF. 5 µl of purified
baculoCTCF protein was loaded on the 10% SDS-PAGE, resolved, and
silver-stained. The band, corresponding to the baculoCTCF, contains
~80-90% of the total protein in this fraction. B, the
same silver-stained baculoCTCF band is selectively recognized by the
anti-CTCF antibodies. The result of Western immunoblot of HeLa cell
lysate (lane 1) and the SF9 cells expressing baculoCTCF
(lane 2) probed with the anti-CTCF antibodies is shown.
Arrows indicate the identical position of CTCF in
A and B. C, the baculoCTCF (lane
2) and CTCF from the nuclear extract from COS6 cells (lane
1) analyzed by EMSA with the 32P-labeled DNA fragment
containing the FPV CTCF binding site (4, 31). The position of the
CTCF·DNA complexes is indicated.
|
|
Affinity Chromatography to Isolate Proteins Which Strongly Interact
with the BaculoCTCF--
BaculoCTCF covalently coupled to matrix was
used to prepare a column as described under "Experimental
Procedures," and nuclear extracts prepared from the chicken erythroid
precursor cells HD3 were passed through the column. Proteins binding to
CTCF with very low affinity or nonspecifically, were eluted by washing
with low-salts buffers. The proteins strongly interacting with CTCF were subsequently eluted with 1 M NaCl. The latter protein
fraction was resolved on 10% SDS-PAGE mini gels. Silver staining
revealed several major and multiple minor protein bands (Fig.
2). To identify the major proteins,
larger amounts of high-salt-eluted proteins were separated by SDS-PAGE
in larger gels, stained with the Coomassie Blue, and the visible bands
were excised. These were subjected to the "in-gel " digestion and
tryptic mixture mass mapping. The protein with a molecular mass of 36 kDa (Fig. 2, lane E2) appeared to be the Y box binding
protein 1, or YB-1 (SwissProt protein data base accession number
Q06066).

View larger version (93K):
[in this window]
[in a new window]
|
Fig. 2.
Isolation of CTCF-associated proteins by the
chromatography on the baculoCTCF-containing column. Silver-stained
10% SDS-PAGE gel loaded with samples obtained from the
baculoCTCF-containing column, and from a control column. The latter was
prepared by the same method as the baculoCTCF column, but using
proteins from the non-infected, CTCF-minus, SF9 cells (see text for
details) bound to Sepharose 4B matrix (lane SF9).
M, protein size markers. The HD3 cell extracts were passed
through both control (lane SF9) and baculoCTCF (lane
E2) columns, and the low affinity bound proteins were washed off
with 150 mm NaCl (panel E1). The proteins binding to the
baculoCTCF with high affinity were eluted with 1 M NaCl
(panel E2). The estimated sizes of these proteins
(panel E2) are indicated.
|
|
CTCF and YB-1 Proteins Co-immunoprecipitate from Cell
Extracts--
To determine if CTCF and YB-1 interact in
vivo we carried out a series of co-immunoprecipitation assays with
the extracts from HeLa cells. Proteins bound by anti-CTCF or anti-YB-1
antibodies were incubated with protein A-Sepharose-4B-Fast, washed,
separated on SDS-PAGE, and analyzed by ECL immunoblotting. Fig.
3A (lane 8) shows
that YB-1 immunoprecipitates obtained from HeLa (lane 8) or
HD3 (lane 9) contain the CTCF band co-migrating with the CTCF protein from the whole HeLa cell lysate (lane 6). CTCF
could not be detected in precipitates obtained with the pre-immune
serum (lane 7), or with antibodies against several nuclear
proteins, including p21, ubiquitous nuclear receptor UR, thyroid
receptor TR , hTAF II 130, and MYC (lanes 1-5,
respectively). CTCF was specifically co-immunoprecipitated with
anti-YB-1 antibodies from extracts obtained from a large number of cell
lines (data not shown), thus suggesting both ubiquitous expression and
association of these two proteins.

View larger version (22K):
[in this window]
[in a new window]
|
Fig. 3.
CTCF is associated in vivo
with the YB1 protein. The in vivo interactions
were investigated by co-immunoprecipitation plus Western blot assays
using the protein from HeLa cells. Anti-YB-1 (A) and
anti-CTCF (B) antibodies were used for co-IPs. A,
cells (~5 × 106) were extracted in the 0.5 M RIPA buffer, and proteins were immunoprecipitated in 0.25 M RIPA buffer with the anti-YB1 antibodies. The
immunoprecipitates were resolved on 10% SDS-PAGE and probed with the
anti-CTCF antibodies. The arrow indicates the positions of
the CTCF protein, co-immunoprecipitated with the anti-YB-1 antibodies
from HeLa (lane 8) and HD3 (lane 9) cell lines,
which coincide with the position of CTCF in the HeLa lysate (lane
6). No CTCF band is observed in the control immunoprecipitate
obtained with the preimmune serum (lane 7) or with a series
of other antibodies described under "Results" (lanes
1-5, respectively). B, the Western assay with the
anti-YB-1 antibodies was performed after immunoprecipitation of the
CTCF protein from HeLa lysates with the CTCF antibodies. The
immunocomplexes were resolved by SDS-PAGE and blotted, and the membrane
was probed with the anti-YB1 antibodies. The arrow indicates
the position of YB-1 in the HeLa cell lysate (lane 1) and
immunoprecipitates with the anti-CTCF antibodies (lane
2).
|
|
In reciprocal experiments, we performed co-immunoprecipitation assays
with anti-CTCF antibodies combined with immunoblotting for YB-1. As
shown in Fig. 3B, the YB-1 protein band was detected in the
CTCF-immunoprecipitated material, and the position of this band was
identical to that of the YB-1 protein in the unfractionated HeLa cell
lysate (Fig. 3B, lane 1). Taken together, these
results indicate that at least a fraction of both YB-1 and CTCF form
specific complexes in vivo.
YB-1 Interacts with CTCF through the CTCF Zinc Finger
Domain--
Although our findings demonstrate that CTCF complexes
in vivo with YB-1, further investigation was required to
determine whether this interaction is direct or mediated by other
proteins. To this end, we produced the three consecutive distinct
domains of CTCF, schematically shown in Fig.
4A, in a bacterial expression
system. These three proteins, CTCF-N+cys, CTCF-ZF+cys, and CTCF-C+cys, contained in-frame additions of a 10xHis-tag at the amino terminus and
a 6xCys residue tag at the carboxyl terminus (Fig. 4A). All three proteins, equally well expressed in E. coli, were
obtained at about 90% purity, as shown by the Coomassie Blue staining
and immunoblotting with anti-His-tag antibodies (Fig. 4, B
and C).

View larger version (39K):
[in this window]
[in a new window]
|
Fig. 4.
YB-1 interacts with CTCF in vitro
through the ZF domain. A, a schematic outline of
the baculoCTCF and of the three major CTCF domains, CTCF-N, CTCF-ZF,
and CTCF-C. Positions of the S-tag, the 10xHis tag, and the 6xCys tag
are indicated. See text for more details. B, SDS-PAGE
analyses of the three CTCF domains expressed in E. coli. The
His-tagged regions of CTCF shown in A were bacterially
produced and purified as described under "Experimental Procedures,"
and 20 µl of the purified fractions was resolved on 10% SDS-PAGE and
stained with Coomassie Blue. C, the three purified domains
were detected by Western blotting with the anti-His tag antibodies
(Sigma). Note that the positions of the His-tag-positive bands,
indicated by arrows, correspond to the major bands seen in
the B. The amino- and carboxyl-terminal domains migrate
abnormally, as described previously (74). D, the three
bacterially expressed domains, and bovine serum albumin used as a
control, were immobilized on a Sepharose 4B matrix and incubated with
the whole cell extract from HeLa cells, then washed with 0.25 M RIPA buffer, and proteins retained on the matrix were
analyzed by SDS-PAGE followed by immunoblotting with the anti-YB-1
antibodies. An arrow indicates the 45-kDa YB-1 protein
eluted from the immobilized CTCF-Zn+cys protein. Other bands are
nonspecific as explained in the text.
|
|
To identify the region(s) of CTCF necessary for interaction with YB-1,
HeLa cell lysates were incubated with immobilized CTCF-N+cys, CTCF-ZF+cys, and CTCF-C+cys proteins. As shown in Fig. 4D
(lane 2), the zinc finger domain of CTCF retained a protein
of about 45 kDa from HeLa lysates, recognized by specific antibodies
for YB-1. YB-1 protein of the same size was also detected in the HeLa cell lysate (Fig. 4D, lane 5). The apparent
molecular mass (45 kDa) of this protein is higher than
previously described for YB-1 (Fig. 2 and Refs. 26, 29, and 36). This
difference may be due to specific post-translational modifications of
YB-1 in HeLa cells (30). No interaction of the HeLa 45-kDa YB-1 with
the matrix-coupled CTCF-N+cys, CTCF-C+cys, or bovine serum albumin proteins was detected (Fig. 4D, lanes 1,
3, and 4). When the same membrane was reprobed
with the preimmune serum, only nonspecific bands outside of the 45-kDa
region were noted (not shown) thus confirming that the 45-kDa band is
the YB-1 of HeLa cells. Further experiments are in progress to identify
more precisely the parts of the CTCF zinc finger domain interacting
with YB-1, and also to delineate the smallest region(s) in YB-1
required to interact with CTCF. Preliminary results of in
vitro pull-down assays with [35S]methionine-labeled
in vitro translated YB-1 and the CTCF-ZF+cys polypeptide on
beads showed retention of the near-full-length YB-1 (not shown). Taken
together, our protein interaction experiments suggest that CTCF and
YB-1 are likely to bind one another without requiring additional partner(s).
CTCF and YB-1 Cooperate in the Regulation of the c-myc
Promoter--
As outlined previously, both CTCF and YB-1 are involved
in several, perhaps intertwined, but mechanistically different
molecular processes related to regulation of gene expression. One model for evaluating functional role(s) for interaction of these proteins was
designed to test if YB-1 affects activity of CTCF-dependent promoters. For this purpose, we performed transient co-transfection studies with vectors expressing full-length CTCF (pCTCF) and YB-1 (pYB-1, or pREP9) and the CAT-based reporter construct pK232-S1CAT containing ~1-kb fragment of the chicken c-myc
5'-noncoding region (Fig. 5A)
bearing the FPV binding site for CTCF (1, 3, 4).

View larger version (23K):
[in this window]
[in a new window]
|
Fig. 5.
CTCF and YB-1 cooperate in repressing the
c-myc promoter. Approximately 105
COS6 cells per well were plated in 12-well plates and transfected, and
CAT assays were performed as described under "Experimental
Procedures." A, the reporter construct p232-S1-CAT
schematic map. It was co-transfected with the vectors expressing CTCF
and/or YB-1. An "empty" vector, pSG5, was used as a control.
B, CAT activities are presented in absolute units.
Transfections were performed in triplicates in five independent
experiments, and statistically significant (by t test)
results are shown.
|
|
As shown in Fig. 5, and in line with our previous observations, ectopic
expression of CTCF led to repression of the c-myc promoter.
In contrast, ectopic expression of YB-1 had no effect on expression
from this reporter. However, a marked synergism of CTCF and YB-1 was
detected in repressing the c-myc promoter when both plasmids
were overexpressed together, especially at the higher input of YB-1
(Fig. 5B). No CTCF-dependent repression, and no
synergy with YB-1, was noted with a mutated PFV site not capable of
CTCF binding (5) (not shown). These results indicate that a functional
interaction between CTCF and YB-1 is important for regulation of the
c-myc promoter.
 |
DISCUSSION |
The initial aim of this study was to develop a reliable system for
identifying proteins that interact with CTCF. To identify such factors,
we employed the full-length CTCF expressed in the baculovirus system
(Fig. 1). Because the purified baculoCTCF possessed major features
characteristic for the native protein (Fig. 1), it was assumed to be
the appropriate bait to utilize for making a reusable affinity matrix
carrying the covalently bound CTCF. The simple procedure for
isolating potential CTCF-interacting partners from cell extracts
has been developed as described under "Results." Employing
this procedure, several proteins, retained on the CTCF matrix, have
been identified. One of them turned out to be another transcription
multifunctional factor, the Y box binding protein 1, YB-1 (Fig. 3).
YB-1 is implicated in regulation of multiple cellular functions. It has
unusual transcription factor activities such as site-specific DNA
unwinding, interaction with RNA, and damaged DNA (30, 39-45). A
multitude of functionally different genes appears to be regulated by
YB-1 (26, 40, 43, 46-50). Among them are germ-line specific genes (20)
and genes associated with cell growth control (24). Moreover, YB-1 is
involved in multiple protein-protein interactions. For instance, it
forms functional heterodimers with transcription factors Pur- , 65 P2
(51), YY-1 (52), PCNA (28), cardiac ankyrin repeat protein CARP (53),
RelA (54), T-antigen (55), and Tat (42). Taken together these
properties of YB-1 indicate diverse and multipurpose utilization of
this factor in cells (for reviews see (20-22, 45, 56-59).
We showed here that CTCF and YB-1 form specific complexes both in
vivo and in vitro, and that interaction with YB-1
requires the zinc finger domain of CTCF (Figs. 3 and 4). Furthermore,
CTCF/YB-1 complexes were observed in various cell types (Fig.
3A) possibly implying "universal" functions for the
association of these two ubiquitously expressed factors. It is tempting
to speculate that CTCF may, therefore, be involved in modulation of at
least some of the multiple functions mediated by YB-1, including those
that are not mediated through direct DNA recognition. It also seems reasonable to suggest in a reciprocal manner that interaction with YB-1
may equip CTCF to perform functions beyond transcriptional regulation
mediated by binding to promoters (5, 6, 9, 16, 17), hormone-responsive
silencers (8, 15), or enhancer-blocking elements in the globin genes
loci or the differentially methylated imprinting control region
upstream of the H19 gene (11-14, 18, 19). Precedent for
this comes from studies on the Wilms' tumor suppressor gene WT1 with a
DNA-binding domain of four zinc fingers capable of mediating binding to
at least two different sequences. WT1 is suggested to be "more then
just a transcription factor" due to its apparent role in RNA
processing and other functions not related to transcription (for review
see Ref. 60).
To test whether interaction with YB-1 might modulate any of many CTCF
functions, we measured the effects of ectopically expressed CTCF on
regulation of promoters bearing CTCF-binding sites (4, 6, 9, 17). The
very first identified regulatory targets for CTCF were the vertebrate
c-myc gene promoters (4-6). We demonstrated here that YB-1
acts synergistically with CTCF to repress the c-myc promoter
(Fig. 5). Expression of YB-1 alone had no effect on promoter activity
(Fig. 5), suggesting that the putative target sequences for YB-1 within
the c-myc promoter are not transcriptionally active. There
are several possible reasons explaining this finding: 1) an optimal
YB-1-binding consensus sequence CTGATTGG(C/T)(C/T)AA (61) is absent; 2)
the only CCAAT motif found in our c-myc reporter constructs
was positioned intronically downstream of the first noncoding exon
within the region not previously identified as important for the
promoter regulation (62-64); and 3) the CCAAT core motif may be masked
from YB-1 by other proteins recognizing the same core sequence,
including NF-Y, NF1/CBP, C/EBP, and the CAAT-binding displacement
factor. Therefore, our results suggest that YB-1 does not have to bind
the c-myc promoter to cooperate with CTCF, but that
interaction with YB-1 is functionally important in regulation of
CTCF-dependent promoters. Whether YB-1/CTCF binding may
have any effect on the CTCF-driven enhancer-blocking (insulator) activity (11-14, 18, 19) remains to be investigated.
Because both CTCF and YB-1 demonstrate multiple interactions with other
proteins, an obviously important question for future studies is whether
the association between CTCF and YB-1 is mutually exclusive with
respect to other YB-1 and CTCF interacting proteins. The quantitative
in vitro interaction assay or EMSA with CTCF, YB-1, and a
third interacting protein would perhaps allow us to assess whether
three or more proteins could form competitive heterodimers or
cooperative heterotrimers.
Our pull-down assays revealed that the zinc finger domain of CTCF is
utilized for interaction with YB-1 (Fig. 4). The concept of alternative
involvement of DNA-binding zinc fingers in protein-protein interactions
is increasingly appreciated (65). Besides DNA binding, the
C2H2 and C2HC classes of ZFs
provide functionally important interactions with other proteins. For
example, transcriptional co-factors of the friend of GATA (FOG)
family bind to GATA proteins by means of multiple ZFs (66).
Interestingly, the unusual single carboxyl-terminal
C2HC-type ZF that is necessary and sufficient for binding
of FOG-1 to GATA-1 is a structural homologue of the carboxyl-terminal
11th ZF of CTCF (not shown).
Because the multiple functions of CTCF are quite different, there must
be specific molecular mechanisms that enable the same protein to
perform distinct functions. Based on the results of DNA binding
experiments with "missing finger" CTCF ZF domains, the multiple
sequence specificity of CTCF was interpreted as reflecting the ability
of CTCF to employ different groups of individual ZFs to recognize
highly divergent sequence (6, 8, 9, 12, 15). One can imagine that the
multiplicity of CTCF effects that derive from occupation of different
DNA sites can be determined by the allosteric effects that result from
assignment of particular group of ZFs for making contacts with DNA
leaving the others for interaction with other proteins. Therefore,
conformational changes in CTCF following interaction with different DNA
sequences are likely to specify its interactions with cofactors that
ultimately determine the biological readout(s).
A growing body of evidence implicates both CTCF and YB-1 in
tumorigenesis. CTCF is located at the cancer-associated
"hot spot" on 16q22 and is found to have a rearranged ZF domain in
some breast cancer samples (67). It is also a negative regulator of the c-myc oncogene for which dysregulation without genomic
alterations is frequently found in different cancers (68-70). On the
other hand, a correlation has been established between YB-1 expression and the development of a malignant phenotype in several tumors including breast cancer (26), colorectal carcinoma (71), ovarian serous
adenocarcinoma (72), and osteosarcoma (73). Normally localized in the
cytoplasm, YB-1 is translocated into the nucleus following
environmental stress (25), and cellular redistribution is reported to
be associated with certain cancer phenotypes characterized by the
P-glycoprotein overexpression (26, 73). Taken together, these findings
suggest that deregulated and/or abnormal CTCF/YB-1 interactions play a
role in tumor development, a subject of our ongoing studies.
 |
ACKNOWLEDGEMENTS |
We thank Drs. S. Newbury, H. Morse III, and
J. Breen for critical reading and suggestions on the manuscript; R. Marais for the pVLH6 vector; H.-D. Royer for the pREP9
(pYB-1) plasmid; and A. Lee and H.-D. Royer for the anti-YB-1
antibodies. We are also grateful to K. Monastyrskaya for helping with
the production of the baculoCTCF, and to E. Pugacheva for helping with
figure preparation.
 |
FOOTNOTES |
*
This work was supported by a Royal Society research grant
and by a research grant from The Research and Equipment
Committee, University of Oxford.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence may be addressed: Section of Molecular
Pathology, Laboratory of Immunopathology, NIAID, National
Institutes of Health, Bldg. 7, Rm. 303, 7 Center Dr., MSC 0760, Bethesda, MD 20892. Tel.: 301-435-1690; Fax: 301-402-0077;
E-mail: vlobanenkov@niaid.nih.gov.
**
To whom correspondence may be addressed: Genetics Laboratory, Dept.
of Biochemistry, University of Oxford, South Parks Rd., Oxford OX1 3QU,
UK. Tel.: 44-1865-2753-14; Fax: 44-1865-2753-18; E-mail:
klenovae@bioch.ox.ac.uk.
Published, JBC Papers in Press, July 20, 2000, DOI 10.1074/jbc.M001538200
2
D. Loukinov and J. Breen, personal communication.
 |
ABBREVIATIONS |
The abbreviations used are:
CTCF, CCTC-binding
protein;
YB-1, Y box binding protein 1;
ZF, zinc finger(s);
bp, base pair(s);
kb, kilobase(s);
EMSA, electrophoretic mobility shift assay;
PAGE, polyacrylamide gel electrophoresis;
CAT, chloramphenicol acetyl
transferase;
baculoCTCF, CTCF purified in the baculovirus system;
RIPA, radioimmunoprecipitation assay;
MALDI-MS, matrix-assisted laser
desorption/ionization mass spectrometry;
CITE, cap independent
translational enhancer.
 |
REFERENCES |
| 1.
|
Lobanenkov, V. V.,
Nicolas, R. H.,
Plumb, M. A.,
Wright, C. A.,
and Goodwin, G. H.
(1986)
Eur. J. Biochem.
159,
181-188
|
| 2.
|
Lobanenkov, V. V.,
and Goodwin, G. H.
(1989)
Proc. Acad. Sci. USSR (Moscow)
309,
741-745
|
| 3.
|
Lobanenkov, V. V.,
Adler, V. V.,
Klenova, E. M.,
Nicolas, R. H.,
and Goodwin, G. H.
(1989)
in
Gene Regulation and AIDS: Transcriptional Activation, Retroviruses and Pathogens
(Papas, T. S., ed)
, pp. 45-68, Portfolio Publishing Corp., Woodlands, TX
|
| 4.
|
Lobanenkov, V. V.,
Nicolas, R. H.,
Adler, V. V.,
Paterson, H.,
Klenova, E. M.,
Polotskaja, A. V.,
and Goodwin, G. H.
(1990)
Oncogene
5,
1743-1753
|
| 5.
|
Klenova, E.,
Nicolas, R.,
Paterson, H.,
Carne, A.,
Heath, C.,
Goodwin, G.,
Neiman, P.,
and Lobanenkov, V.
(1993)
Mol. Cell. Biol.
13,
7612-7624
|
| 6.
|
Filippova, G.,
Fagerlie, S.,
Klenova, E.,
Myers, C.,
Dehner, Y.,
Goodwin, G.,
Neiman, P.,
Collins, S.,
and Lobanenkov, V.
(1996)
Mol. Cell. Biol.
16,
2802-2813
|
| 7.
|
Tevosian, S. G.,
Gromova, E. S.,
Adler, V. V.,
and Lobanenkov, V. V.
(1991)
Mol. Biol. (Moscow)
25,
1013-1023
|
| 8.
|
Burcin, M.,
Arnold, R.,
Lutz, M.,
Kaiser, B.,
Runge, D.,
Lottspeich, F.,
Filippova, G. N.,
Lobanenkov, V. V.,
and Renkawitz, R.
(1997)
Mol. Cell. Biol.
17,
1281-1288
|
| 9.
|
Vostrov, A. A.,
and Quitschke, W. W.
(1997)
J. Biol. Chem.
272,
33353-33359
|
| 10.
|
Szabo, P. E.,
Tang, S.-H. E.,
Rentsendorj, A.,
Pfeifer, G. P.,
and Mann, J. R.
(2000)
Curr. Biol.
10,
607-610
|
| 11.
|
Saitoh, N.,
Bell, A. C.,
Recillas-Targa, F.,
West, A. G.,
Simpson, M.,
Pikaart, M.,
and Felsenfeld, G.
(2000)
EMBO J.
19,
2315-2322
|
| 12.
|
Kanduri, C.,
Pant, V.,
Loukinov, D.,
Pugacheva, E.,
Qi, C.-F.,
Wolffe, A.,
Ohlsson, R.,
and Lobanenkov, V.
(2000)
Curr. Biol.
10,
853-856
|
| 13.
|
Bell, A. C.,
West, A. G.,
and Felsenfeld, G.
(1999)
Cell
98,
387-396
|
| 14.
|
Bell, A. C.,
and Felsenfeld, G.
(1999)
Curr. Opin. Genet. Dev.
9,
191-198
|
| 15.
|
Awad, T. A.,
Bigler, J.,
Ulmer, J. E.,
Hu, Y. J.,
Moore, J. M.,
Lutz, M.,
Neiman, P. E.,
Collins, S. J.,
Renkawitz, R.,
Lobanenkov, V. V.,
and Filippova, G. N.
(1999)
J. Biol. Chem.
274,
27092-27098
|
| 16.
|
Quitschke, W. W.
(1994)
J. Biol. Chem.
269,
21229-21233
|
| 17.
|
Yang, Y.,
Quitschke, W. W.,
Vostrov, A. A.,
and Brewer, G. J.
(1999)
J. Neurochem.
73,
2286-2298
|
| 18.
|
Szabó, P.,
Tang, S.-H.,
Rentsendorj, A.,
Pfeifer, G.,
and Mann, J.
(2000)
Curr. Biol.
10,
607-610
|
| 19.
|
Kanduri, C.,
Holmgren, C.,
Franklin, G.,
Pilartz, M.,
Ullerås, E.,
Kanduri, M.,
Liu, L.,
Ginjala, V.,
Ulleras, E.,
Mattsson, R.,
and Ohlsson, R.
(2000)
Curr. Biol.
10,
449-457
|
| 20.
|
Wolffe, A. P.
(1994)
Bioessays
16,
245-251
|
| 21.
|
Wolffe, A. P.,
Tafuri, S.,
Ranjan, M.,
and Familari, M.
(1992)
New Biol.
4,
290-298
|
| 22.
|
Sommerville, J.,
and Ladomery, M.
(1996)
Chromosoma (Berl.)
104,
469-478
|
| 23.
|
Sommerville, J.,
and Ladomery, M.
(1996)
FASEB J.
10,
435-443
|
| 24.
|
Ladomery, M.,
and Sommerville, J.
(1995)
Bioessays
17,
9-11
|
| 25.
|
Koike, K.,
Uchiumi, T.,
Ohga, T.,
Toh, S.,
Wada, M.,
Kohno, K.,
and Kuwano, M.
(1997)
FEBS Lett.
417,
390-394
|
| 26.
|
Bargou, R. C.,
Jurchott, K.,
Wagener, C.,
Bergmann, S.,
Metzner, S.,
Bommert, K.,
Mapara, M. Y.,
Winzer, K. J.,
Dietel, M.,
Dorken, B.,
and Royer, H. D.
(1997)
Nat. Med.
3,
447-450
|
| 27.
|
Sabath, D. E.,
Podolin, P. L.,
Comber, P. G.,
and Prystowsky, M. B.
(1990)
J. Biol. Chem.
265,
12671-12678
|
| 28.
|
Ise, T.,
Nagatani, G.,
Imamura, T.,
Kato, K.,
Takano, H.,
Nomoto, M.,
Izumi, H.,
Ohmori, H.,
Okamoto, T.,
Ohga, T.,
Uchiumi, T.,
Kuwano, M.,
and Kohno, K.
(1999)
Cancer Res.
59,
342-346
|
| 29.
|
Grant, C. E.,
and Deeley, R. G.
(1993)
Mol. Cell. Biol.
13,
4186-4196
|
| 30.
|
MacDonald, G. H.,
Itoh-Lindstrom, Y.,
and Ting, J. P.
(1995)
J. Biol. Chem.
270,
3527-3533
|
| 31.
|
Klenova, E. M.,
Nicolas, R. H.,
Paterson, H. F.,
Carne, A. F.,
Heath, C. M.,
Goodwin, G. H.,
Neiman, P. E.,
and Lobanenkov, V. V.
(1993)
Mol. Cell. Biol.
13,
7612-7624
|
| 32.
|
Beug, H.,
von Kirchbach, A.,
Doderlein, G.,
Conscience, J. F.,
and Graf, T.
(1979)
Cell
18,
375-390
|
| 33.
|
Shevchenko, A.,
Wilm, M.,
Vorm, O.,
and Mann, M.
(1996)
Anal. Chem.
68,
850-858
|
| 34.
|
Patterson, S. D.,
and Aebersold, R.
(1995)
Electrophoresis
16,
1791-1814
|
| 35.
|
Towatari, M.,
May, G. E.,
Marais, R.,
Perkins, G. R.,
Marshall, C. J.,
Cowley, S.,
and Enver, T.
(1995)
J. Biol. Chem.
270,
4101-4107
|
| 36.
|
Chen, C. Y.,
Gherzi, R.,
Andersen, J. S.,
Gaietta, G.,
Jurchott, K.,
Royer, H. D.,
Mann, M.,
and Karin, M.
(2000)
Genes Dev.
14,
1236-1248
|
| 37.
|
Plumb, M. A.,
Lobanenkov, V. V.,
Nicolas, R. H.,
Wright, C. A.,
Zavou, S.,
and Goodwin, G. H.
(1986)
Nucleic Acids Res.
14,
7675-7693
|
| 38.
|
Lobanenkov, V.,
Nicolas, R.,
Adler, V.,
Paterson, H.,
Klenova, E.,
Polotskaja, A.,
and Goodwin, G.
(1990)
Oncogene
5,
1743-1753
|
| 39.
|
Hasegawa, S. L.,
Doetsch, P. W.,
Hamilton, K. K.,
Martin, A. M.,
Okenquist, S. A.,
Lenz, J.,
and Boss, J. M.
(1991)
Nucleic Acids Res.
19,
4915-4920
|
| 40.
|
Zou, Y.,
and Chien, K. R.
(1995)
Mol. Cell. Biol.
15,
2972-2982
|
| 41.
|
Duh, J. L.,
Zhu, H.,
Shertzer, H. G.,
Nebert, D. W.,
and Puga, A.
(1995)
J. Biol. Chem.
270,
30499-30507
|
| 42.
|
Ansari, S. A.,
Safak, M.,
Gallia, G. L.,
Sawaya, B. E.,
Amini, S.,
and Khalili, K.
(1999)
J. Gen. Virol.
80,
2629-2638
|
| 43.
|
Ohmori, M.,
Shimura, H.,
Shimura, Y.,
and Kohn, L. D.
(1996)
Mol. Endocrinol.
10,
76-89
|
| 44.
|
Boulikas, T.
(1996)
Anticancer Res.
16,
225-242
|
| 45.
|
Swamynathan, S. K.,
Nambiar, A.,
and Guntaka, R. V.
(2000)
Biochem. J.
348,
297-305
|
| 46.
|
Kashanchi, F.,
Duvall, J. F.,
Dittmer, J.,
Mireskandari, A.,
Reid, R. L.,
Gitlin, S. D.,
and Brady, J. N.
(1994)
J. Virol.
68,
561-565
|
| 47.
|
Sawaya, B. E.,
Khalili, K.,
and Amini, S.
(1998)
J. Gen. Virol.
79,
239-246
|
| 48.
|
Mertens, P. R.,
Harendza, S.,
Pollock, A. S.,
and Lovett, D. H.
(1997)
J. Biol. Chem.
272,
22905-22912
|
| 49.
|
Montani, V.,
Taniguchi, S. I.,
Shong, M.,
Suzuki, K.,
Ohmori, M.,
Giuliani, C.,
Napolitano, G.,
Saji, M.,
Fiorentino, B.,
Reimold, A. M.,
Ting, J. P.,
Kohn, L. D.,
and Singer, D. S.
(1998)
Endocrinology
139,
280-289
|
| 50.
|
Asakuno, K.,
Kohno, K.,
Uchiumi, T.,
Kubo, T.,
Sato, S.,
Isono, M.,
and Kuwano, M.
(1994)
Biochem. Biophys. Res. Commun.
199,
1428-1435
|
| 51.
|
Mertens, P. R.,
Alfonso-Jaume, M. A.,
Steinmann, K.,
and Lovett, D. H.
(1998)
J. Biol. Chem.
273,
32957-32965
|
| 52.
|
Li, W. W.,
Hsiung, Y.,
Wong, V.,
Galvin, K.,
Zhou, Y.,
Shi, Y.,
and Lee, A. S.
(1997)
Mol. Cell. Biol.
17,
61-68
|
| 53.
|
Zou, Y.,
Evans, S.,
Chen, J.,
Kuo, H. C.,
Harvey, R. P.,
and Chien, K. R.
(1997)
Development
124,
793-804
|
| 54.
|
Raj, G. V.,
Safak, M.,
MacDonald, G. H.,
and Khalili, K.
(1996)
J. Virol.
70,
5944-5953
|
| 55.
|
Safak, M.,
Gallia, G. L.,
Ansari, S. A.,
and Khalili, K.
(1999)
J. Virol.
73,
10146-10157
|
| 56.
|
Swamynathan, S. K.,
Nambiar, A.,
and Guntaka, R. V.
(1998)
FASEB J.
12,
515-522
|
| 57.
|
Ladomery, M.
(1997)
Bioessays
19,
903-909
|
| 58.
|
Wolffe, A. P.,
and Meric, F.
(1996)
Int. J. Biochem. Cell Biol.
28,
247-257
|
| 59.
|
Wolffe, A. P.
(1994)
Dev. Genet.
15,
463-470
|
| 60.
|
Englert, C.
(1998)
Trends Biochem. Sci.
23,
389-393
|
| 61.
|
Didier, D. K.,
Schiffenbauer, J.,
Woulfe, S. L.,
Zacheis, M.,
and Schwartz, B. D.
(1988)
Proc. Natl. Acad. Sci. U. S. A.
85,
7322-7326
|
| 62.
|
Asselin, C.,
Nepveu, A.,
and Marcu, K. B.
(1989)
Oncogene
4,
549-558
|
| 63.
|
Marcu, K. B.,
Bossone, S. A.,
and Patel, A. J.
(1992)
Annu. Rev. Biochem.
61,
809-860
|
| 64.
|
Potter, M.,
and Marcu, K. B.
(1997)
Curr. Top. Microbiol. Immunol.
224,
1-17
|
| 65.
|
Turner, J.,
and Melton, D. A.
(1999)
Trends Biochem. Sci.
24,
236-240
|
| 66.
|
Fox, A. H.,
Liew, C.,
Holmes, M.,
Kowalski, K.,
Mackay, J.,
and Crossley, M.
(1999)
EMBO J.
18,
2812-2822
|
| 67.
|
Filippova, G.,
Lindblom, A.,
Meincke, L.,
Klenova, E.,
Neiman, P.,
Collins, S.,
Doggett, N.,
and Lobanenkov, V.
(1998)
Genes Chromosomes Cancer
22,
26-36
|
| 68.
|
Spencer, C. A.,
and Groudine, M.
(1991)
Adv. Cancer Res.
56,
1-48
|
| 69.
|
Shiu, R. P.,
Watson, P. H.,
and Dubik, D.
(1993)
Clin. Chem.
39,
353-355
|
| 70.
|
Fearon, E. R.,
and Dang, C. V.
(1999)
Curr. Biol.
9,
R62-R65
|
| 71.
|
Shibao, K.,
Takano, H.,
Nakayama, Y.,
Okazaki, K.,
Nagata, N.,
Izumi, H.,
Uchiumi, T.,
Kuwano, M.,
Kohno, K.,
and Itoh, H.
(1999)
Int. J. Cancer
83,
732-737
|
| 72.
|
Kamura, T.,
Yahata, H.,
Amada, S.,
Ogawa, S.,
Sonoda, T.,
Kobayashi, H.,
Mitsumoto, M.,
Kohno, K.,
Kuwano, M.,
and Nakano, H.
(1999)
Cancer
85,
2450-2454
|
| 73.
|
Oda, Y.,
Sakamoto, A.,
Shinohara, N.,
Ohga, T.,
Uchiumi, T.,
Kohno, K.,
Tsuneyoshi, M.,
Kuwano, M.,
and Iwamoto, Y.
(1998)
Clin. Cancer Res.
4,
2273-2277
|
| 74.
|
Klenova, E. M.,
Nicolas, R. H., U, S.,
Carne, A. F.,
Lee, R. E.,
Lobanenkov, V. V.,
and Goodwin, G. H.
(1997)
Nucleic Acids Res.
25,
466-474
|
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
J. Zlatanova and P. Caiafa
CTCF and its protein partners: divide and rule?
J. Cell Sci.,
May 1, 2009;
122(9):
1275 - 1284.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Renda, I. Baglivo, B. Burgess-Beusse, S. Esposito, R. Fattorusso, G. Felsenfeld, and P. V. Pedone
Critical DNA Binding Interactions of the Insulator Protein CTCF: A SMALL NUMBER OF ZINC FINGERS MEDIATE STRONG BINDING, AND A SINGLE FINGER-DNA INTERACTION CONTROLS BINDING AT IMPRINTED LOCI
J. Biol. Chem.,
November 16, 2007;
282(46):
33336 - 33345.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J.-i. Komura, H. Ikehata, and T. Ono
Chromatin fine structure of the c-MYC insulator element/DNase I-hypersensitive site I is not preserved during mitosis
PNAS,
October 2, 2007;
104(40):
15741 - 15746.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Roberts, A. C. Scott, M. R. Howard, G. Breen, V. J. Bubb, E. Klenova, and J. P. Quinn
Differential Regulation of the Serotonin Transporter Gene by Lithium Is Mediated by Transcription Factors, CCCTC Binding Protein and Y-Box Binding Protein 1, through the Polymorphic Intron 2 Variable Number Tandem Repeat
J. Neurosci.,
March 14, 2007;
27(11):
2793 - 2801.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. Chernukhin, S. Shamsuddin, S. Y. Kang, R. Bergstrom, Y.-W. Kwon, W. Yu, J. Whitehead, R. Mukhopadhyay, F. Docquier, D. Farrar, et al.
CTCF Interacts with and Recruits the Largest Subunit of RNA Polymerase II to CTCF Target Sites Genome-Wide
Mol. Cell. Biol.,
March 1, 2007;
27(5):
1631 - 1648.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. Torrano, J. Navascues, F. Docquier, R. Zhang, L. J. Burke, I. Chernukhin, D. Farrar, J. Leon, M. T. Berciano, R. Renkawitz, et al.
Targeting of CTCF to the nucleolus inhibits nucleolar transcription through a poly(ADP-ribosyl)ation-dependent mechanism
J. Cell Sci.,
May 1, 2006;
119(9):
1746 - 1759.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P.-A. Defossez, K. F. Kelly, G. J. P. Filion, R. Perez-Torrado, F. Magdinier, H. Menoni, C. L. Nordgaard, J. M. Daniel, and E. Gilson
The Human Enhancer Blocker CTC-binding Factor Interacts with the Transcription Factor Kaiso
J. Biol. Chem.,
December 30, 2005;
280(52):
43017 - 43023.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Docquier, D. Farrar, V. D'Arcy, I. Chernukhin, A. F. Robinson, D. Loukinov, S. Vatolin, S. Pack, A. Mackay, R. A. Harris, et al.
Heightened Expression of CTCF in Breast Cancer Cells Is Associated with Resistance to Apoptosis
Cancer Res.,
June 15, 2005;
65(12):
5112 - 5122.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Klenova, A. C. Scott, J. Roberts, S. Shamsuddin, E. A. Lovejoy, S. Bergmann, V. J. Bubb, H.-D. Royer, and J. P. Quinn
YB-1 and CTCF Differentially Regulate the 5-HTT Polymorphic Intron 2 Enhancer Which Predisposes to a Variety of Neurological Disorders
J. Neurosci.,
June 30, 2004;
24(26):
5966 - 5973.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. Pant, S. Kurukuti, E. Pugacheva, S. Shamsuddin, P. Mariano, R. Renkawitz, E. Klenova, V. Lobanenkov, and R. Ohlsson
Mutation of a Single CTCF Target Site within the H19 Imprinting Control Region Leads to Loss of Igf2 Imprinting and Complex Patterns of De Novo Methylation upon Maternal Inheritance
Mol. Cell. Biol.,
April 15, 2004;
24(8):
3497 - 3504.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. J. McConnell, N. Chevallier, W. Berkofsky-Fessler, J. M. Giltnane, R. B. Malani, L. M. Staudt, and J. D. Licht
Growth Suppression by Acute Promyelocytic Leukemia-Associated Protein PLZF Is Mediated by Repression of c-myc Expression
Mol. Cell. Biol.,
December 15, 2003;
23(24):
9375 - 9388.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
U. Raffetseder, B. Frye, T. Rauen, K. Jurchott, H.-D. Royer, P. L. Jansen, and P. R. Mertens
Splicing Factor SRp30c Interaction with Y-box Protein-1 Confers Nuclear YB-1 Shuttling and Alternative Splice Site Selection
J. Biol. Chem.,
May 9, 2003;
278(20):
18241 - 18248.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Higashi, Y. Inagaki, N. Suzuki, S. Mitsui, A. Mauviel, H. Kaneko, and I. Nakatsuka
Y-box-binding Protein YB-1 Mediates Transcriptional Repression of Human alpha 2(I) Collagen Gene Expression by Interferon-gamma
J. Biol. Chem.,
February 7, 2003;
278(7):
5156 - 5162.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. S. Coles, P. Diamond, L. Lambrusco, J. Hunter, J. Burrows, M. A. Vadas, and G. J. Goodall
A novel mechanism of repression of the vascular endothelial growth factor promoter, by single strand DNA binding cold shock domain (Y-box) proteins in normoxic fibroblasts
Nucleic Acids Res.,
November 15, 2002;
30(22):
4845 - 4854.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. E. Capowski, S. Esnault, S. Bhattacharya, and J. S. Malter
Y Box-Binding Factor Promotes Eosinophil Survival by Stabilizing Granulocyte-Macrophage Colony-Stimulating Factor mRNA
J. Immunol.,
November 15, 2001;
167(10):
5970 - 5976.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. E. J. Rasko, E. M. Klenova, J. Leon, G. N. Filippova, D. I. Loukinov, S. Vatolin, A. F. Robinson, Y. J. Hu, J. Ulmer, M. D. Ward, et al.
Cell Growth Inhibition by the Multifunctional Multivalent Zinc-Finger Factor CTCF
Cancer Res.,
August 1, 2001;
61(16):
6002 - 6007.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. M. Klenova, I. V. Chernukhin, A. El-Kady, R. E. Lee, E. M. Pugacheva, D. I. Loukinov, G. H. Goodwin, D. Delgado, G. N. Filippova, J. León, et al.
Functional Phosphorylation Sites in the C-Terminal Region of the Multivalent Multifunctional Transcriptional Factor CTCF
Mol. Cell. Biol.,
March 15, 2001;
21(6):
2221 - 2234.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
D. R. Marenstein, M. T. A. Ocampo, M. K. Chan, A. Altamirano, A. K. Basu, R. J. Boorstein, R. P. Cunningham, and G. W. Teebor
Stimulation of Human Endonuclease III by Y Box-binding Protein 1 (DNA-binding Protein B). INTERACTION BETWEEN A BASE EXCISION REPAIR ENZYME AND A TRANSCRIPTION FACTOR
J. Biol. Chem.,
June 8, 2001;
276(24):
21242 - 21249.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. T. Norman, G. E. Lindahl, K. Shakib, A. En-Nia, E. Yilmaz, and P. R. Mertens
The Y-box Binding Protein YB-1 Suppresses Collagen alpha 1(I) Gene Transcription via an Evolutionarily Conserved Regulatory Element in the Proximal Promoter
J. Biol. Chem.,
August 3, 2001;
276(32):
29880 - 29890.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2000 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|